scholarly journals Could Adjuvant Chemotherapy Improve Prognosis for Cervical Cancer Patients with Elevated Pretreatment Serum Squamous-Cell Carcinoma Antigen?

2021 ◽  
Vol Volume 14 ◽  
pp. 109-116
Author(s):  
Zhen Yuan ◽  
Dongyan Cao ◽  
Ying Zhang ◽  
Keng Shen ◽  
Jiaxin Yang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Carcinoma Antigen ◽  
Pretreatment Serum

scholarly journals Preoperative SCC-Ag as a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors

2020 ◽  
Author(s):  
Hong-tao Guo ◽  
Xue-han Bi ◽  
Ting Lei ◽  
Xiao Lv ◽  
Guang Yao ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Distant Metastasis ◽  
Adjuvant Radiotherapy ◽  
Disease Free Survival ◽  
Free Survival

Abstract Background For cervical cancer patients whose tumors display a combination of intermediate risk factors, postoperative radiation with or without adjuvant chemotherapy is suggested for them. However, who should be administered with adjuvant chemotherapy is unknown. The current study was designed to explore the clinical value of squamous cell carcinoma antigen in guiding the use of adjuvant chemotherapy in cervical cancer patients.Methods A retrospective study of 301 cervical cancer patients treated by surgery and adjuvant treatment from Mar. 2005 to Mar. 2015 was performed. All patients were divided into two groups according to receiving adjuvant chemotherapy or not. Overall survival (OS), disease-free survival (DFS) were compare between patients who did and did not receive adjuvant radiotherapy. Multivariate analysis was employed to detect clinical factors associated with disease-free survival, local recurrence-free survival and distant metastasis-free survival.Results For patients with high pre-treatment squamous cell carcinoma level, DFS and OS in adjuvant chemo-radiotherapy group were higher than that in adjuvant radiotherapy group. Besides, the rates of distant metastasis were found lower in patients who did receive adjuvant chemotherapy than those who did not. For patients with upper low pre-treatment squamous cell carcinoma level, the 5-year OS and DFS were similar between groups of adjuvant chemo-radiotherapy and adjuvant radiotherapy. Multivariable analysis indicated adjuvant chemotherapy was independent predictors of DFS and distant metastasis-free survival in patients with high squamous cell carcinoma level.Conclusion Squamous cell carcinoma can serve as an indication for the administration of adjuvant chemotherapy in cervical cancer patients.

Squamous Cell Carcinoma Antigen Isoforms in Serum from Cervical Cancer Patients

Tumor Biology ◽  
2006 ◽  
Vol 27 (3) ◽  
pp. 142-152 ◽  
Author(s):  
Eva Röijer ◽  
Henk W.A. de Bruijn ◽  
Ulrika Dahlén ◽  
Ka ten Hoor ◽  
Maria Lundin ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Carcinoma Antigen

Molecular detection of squamous cell carcinoma antigen transcripts in peripheral blood of cancer patients

2006 ◽  
Vol 44 (5) ◽  
Author(s):  
Nur Buyru ◽  
Hatice Tigli ◽  
Derya Duranyildiz ◽  
Nejat Dalay
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Cancer Detection ◽  
Squamous Cell ◽  
Peripheral Blood ◽  
Serum Marker ◽  
Diagnostic Tools ◽  
Squamous Cell Carcinoma Antigen

AbstractThe squamous cell carcinoma antigen (SCC-Ag) has been widely applied as a serum marker in different kinds of cancer and was reported as a target gene for the detection of tumor cells in peripheral blood in cervical cancer. Nucleic acids released into the circulation are non-invasive diagnostic tools for cancer detection. The objective of this study was to determine the utility of SCC-Ag mRNA as a cancer detection marker in blood of cancer patients. For this purpose, 77 blood samples from five gastric cancer, 23 laryngeal cancer, 31 lung cancer, nine esophageal, and nine cervical cancer patients were analyzed. The

Clinical Value of Routine Serum Squamous Cell Carcinoma Antigen in Follow-Up of Patients With Early-Stage Cervical Cancer

2001 ◽  
Vol 19 (19) ◽  
pp. 3960-3966 ◽  
Author(s):  
Martha D. Esajas ◽  
Jitze M. Duk ◽  
Henk W.A. de Bruijn ◽  
Jan G. Aalders ◽  
Pax H.B. Willemse ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Early Stage ◽  
Elevated Serum ◽  
Squamous Cell Carcinoma Antigen ◽  
Early Stage Cervical Cancer

PURPOSE: To investigate the contribution to recurrence detection and survival of serum squamous cell carcinoma antigen (SCC-ag) analysis in the follow-up of early-stage cervical cancer patients. PATIENTS AND METHODS: Follow-up data were evaluated in patients with early-stage squamous cell cervical cancer treated by radical hysterectomy and pelvic lymphadenectomy with or without radiotherapy. Routine serum SCC-ag determination was performed at each follow-up visit. RESULTS: Recurrent disease occurred in 35 (16%) of 225 patients and was preceded or accompanied by serum SCC-ag elevation 26 times (sensitivity, 74%). In five (14%) of these 35 patients, elevated serum SCC-ag was the first measured clinical indicator. Desite salvage therapy, all five patients died of disease. In the other 31 patients (21 with serum SCC-ag elevation), either symptoms and/or positive signs led to recurrence detection. Median survival time after recurrence was worse (9 months; range, 2 to 112+) for patients with an elevated serum SCC-ag value at recurrence in comparison with patients with normal serum SCC-ag values (20 months; range, 4 to 96; P < .01). In 23 of the 190 patients without recurrences, serum SCC-ag values became falsely elevated. In 16 of these 23 patients, the repeat sample after 6 weeks showed a normal SCC-ag, and in seven patients benign (especially skin) disorders were found. CONCLUSION: Serum SCC-ag analysis results in earlier recurrence detection in a small proportion (14%) of patients but did not contribute to better survival. As long as treatment possibilities for recurrent cervical cancer patients are not improved, serum SCC-ag analysis should not be carried out in routine follow-up.

Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence

2016 ◽  
Vol 142 (1) ◽  
pp. 115-119 ◽  
Author(s):  
Michela Salvatici ◽  
Maria T. Achilarre ◽  
Maria T. Sandri ◽  
Sara Boveri ◽  
Zanagnolo Vanna ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Early Diagnosis ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Carcinoma Antigen
Sign in / Sign up

Export Citation Format

Share Document